TY  - JOUR
TI  - The Comparison of Effects of Applications of Compound 48/80 and Mast Cell Mediator Suspension on Inflammation in Rats: A Methodological Study for Acute Inflammatory Pain
AB  - Objective: Inflammation underlies the pathological basis of most diseases. Substance-P is a key mediator that participates in various inflammatoryprocesses and painful conditions. Mast cells (MCs) have a key role in inflammatory processes via mediators released from their granules. Theexperimental models for the investigation of pathogenesis and treatment of inflammatory diseases represent merely certain characteristics ofinflammatory cases, therefore, more comprehensive models are required. We aimed to compare effects of administrations of the compound-48/80and mast cell mediator suspension (MCMS) obtained from peritoneal MCs on the inflammation in rats.Methods: Rats were divided into five groups (n=6): Intraperitoneally, Control group received 0.2 ml saline; C-48/80 group received 2 mg/kgcompound-48/80; MCMS group received 0.2 ml MCMS; Cr+C-48/80 group received 10 mg/kg cromolyn plus compound-48/80; Cr+MCMS groupreceived cromolyn plus MCMS. Potent inflammatory markers, plasma substance-P levels, and number and degranulation of dural MCs weremeasured. Data were analyzed using one-way ANOVA followed by Dunnett’s post hoc test.Results: Compound-48/80 increased plasma substance-P levels (p<0.05) and dural MC-degranulation (p<0.001). Likewise, MCMS increasedsubstance-P levels and dural MC-degranulation (p<0.001) as well as number of dural MCs (p<0.01). MC stabilizer cromolyn inhibited increases in theparameters induced by compound-48/80 and MCMS (p<0.01 and p<0.05, respectively).Conclusion: MCMS administration had greater impact to increase the plasma substance-P levels and number and degranulation of dural MCs thanthat of the compound-48/80 administration. The results demonstrate the potent inflammatory effect of MCMS treatment over the compund-48/80administration. Administration of MCMS could be a useful tool to study inflammatory conditions.
AU  - Kilinc, Erkan
AU  - ÇETINKAYA, AYHAN
AU  - dagistan, yasar
AU  - Töre, Fatma
DO  - 10.5152/clinexphealthsci.2018.923
PY  - 2019
JO  - Clinical and Experimental Health Sciences
VL  - 9
IS  - 1
SN  - 2459-1459
SP  - 34
EP  - 41
DB  - TRDizin
UR  - http://search/yayin/detay/375256
ER  -